Page 4,827«..1020..4,8264,8274,8284,829..4,8404,850..»

Pitt reseachers join nationwide head-injury study

Posted: Published on October 23rd, 2013

October 22, 2013 12:08 PM Share with others: Pittsburgh Post-Gazette University of Pittsburgh researchers are among those from 20 institutions in the U.S. who will participate in a $18.8 million NIH study on traumatic brain injury. It will be part of one of the largest international research collaborations ever coordinated by funding agencies. David Okonkwo, associate professor of neurological surgery and clinical director of the Brain Trauma Research Center at Pitt, will lead the local part of the study. The five-year study will be administered through University of California San Francisco. The Centers for Disease Control and Prevention estimates that 2 percent of the U.S. population lives with disabilities caused by traumatic brain injuries or TBI, with an annual cost of care at $77 billion. Roughly 1.7 million people seek medical attention for TBI each year. In the new study, scientists aim to refine and improve diagnosis and treatment of TBI whether from car accidents, football injuries, battle wounds or other causes. Such brain injuries often go undiagnosed or are misdiagnosed and can be under treated because symptoms can be misunderstood and insidious. Geoffrey Manley, a UCSF neurosurgeon who will serve as the U.S. research teams primary liaison to the … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Pitt reseachers join nationwide head-injury study

Traumatic Brain Injury Research Advances with $18.8M NIH Award

Posted: Published on October 23rd, 2013

The National Institutes of Health is awarding $18.8 million over five years to support worldwide research on concussion and traumatic brain injury. The NIH award, part of one of the largest international research collaborations ever coordinated by funding agencies, will be administered through UC San Francisco. The award supports a team of U.S. researchers at more than 20 institutions throughout the country who are participating in the International Traumatic Brain Injury (InTBIR) Initiative, a collaborative effort of the European Commission, the Canadian Institutes of Health Research (CIHR), the National Institutes of Health (NIH) and the U.S. Department of Defense (DOD). Although the potential long-term harms due to concussions and blows to the head have gained more attention recently due in part to media coverage of the experiences of athletes and of soldiers returning from the Middle East traumatic brain injuries, or TBI, that results from automobile crashes or other common accidents impacts many more people. Many of those who are affected by TBI are never diagnosed, according to UCSF neurosurgeon Geoffrey Manley, MD, PhD, a principal investigator for the grant who will serve as the U.S. research teams primary liaison to the NIH,and thechief of neurosurgery at the UCSF-affiliated San … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Traumatic Brain Injury Research Advances with $18.8M NIH Award

Mental health system 'not to blame' for suicide

Posted: Published on October 23rd, 2013

The supervision, treatment and care of a severely depressed Perth woman before she flew to Mexico and committed suicide was not optimal, but was not below accepted practice at the time, a WA Coroner has found. The 39-year-old woman, known as Ms D, travelled to Mexico in April 2008 after she discharged herself from King Edward Memorial Hospital earlier that month and was placed on a community treatment order. She had been made an involuntary patient in February but her involuntary status was later removed by the Mental Health Review Board despite hospital staff having found evidence of her suicide plan. A coronial inquest into her death was held earlier this year. In findings handed down today, acting State Coroner Evelyn Vicker found the woman, who was deeply resistant to conventional medication and hospitalisation, "well knew how to mask her real presentation with a facade of seeming to comply with treatment". Ms Vicker said the woman used a hearing before the MHRB "to convince the members she was quite rational and able to make appropriate choices for her wellbeing". Ms Vicker said: "She effectively convinced the MHRB she would be better off without the restrictions imposed by her involuntary status". … Continue reading →

Posted in MS Treatment | Comments Off on Mental health system 'not to blame' for suicide

Increase in Convenient Treatment Options Drives the Testosterone Replacement Therapy Market, According to New Report …

Posted: Published on October 23rd, 2013

San Jose, CA (PRWEB) October 22, 2013 Follow us on LinkedIn - The market for Testosterone Replacement Therapy (TRT) has been witnessing healthy growth over the last decade. The introduction of topical gel formulations at the turn of the century has been a significant milestone in the evolution of the TRT market. In subsequent years, manufacturers launched several gel based products with varying efficacy levels. Being a condition usually associated with aging, the aging world population is benefiting the TRT market. Although prevalence rates remain high, a very small share of the addressable market is presently being served. This presents tremendous untapped potential for further growth in the market, as awareness and product choices improve. Although prospects for topical gels and solutions appear bright, injectables have been witnessing a rise in adoption over the recent years. With new injectables and oral formulations in pipeline, the TRT market is likely to witness a trend towards more convenient and efficacious therapies. Awareness and diagnosis remain critical to the future of the market. Given the stigma attached to hormone therapy, significant marketing activity is required to raise awareness and improve sales of TRT products. Aggressive marketing campaigns by pharmaceutical companies as well as … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Increase in Convenient Treatment Options Drives the Testosterone Replacement Therapy Market, According to New Report …

Ore. hormone therapy, cancer case goes to trial

Posted: Published on October 23rd, 2013

by Cornelius Swart, KGW.com Staff kgw.com Posted on October 22, 2013 at 5:07 PM Updated today at 5:59 AM PORTLAND-- The US Supreme Court ruled Monday that a case between a West Linn woman and Danish pharmaceutical company Novo Nordisk A/S will have to go trial. Suzanne Lukas-Werner claimed she got breast cancer in 2009 after using the Novo Nordisk hormone replacement therapy drug known as Activella for six years. She said she underwent a mastectomy of her right breast and three lymph nodes were removed. She went through several treatments of radiation and chemotherapy. Lukas-Werner filed a claim against Novo Nordisk and her Lake Oswego doctor in September 2010. She made a public statement to the press on Tuesday. "We've been kind of under attack with Novo Nordisk, said Lukas-Werner. We're the David versus the Goliath and Im surprised we've gotten this far. I was very surprised by the supreme court verdict. I'm very grateful." According to Law360, Novo Nordisk had tried to assert that an Oregon court had no jurisdiction over the drugmaker. Tuesday's ruling means the company will have to open its records to Lukas-Werner's attorneys and that the case is clear to go before a Multnomah … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Ore. hormone therapy, cancer case goes to trial

Stem Cell Research Radio Broadcast Glenbrook South 2013 John, Alex – Video

Posted: Published on October 23rd, 2013

Stem Cell Research Radio Broadcast Glenbrook South 2013 John, Alex By: John Donaubauer … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem Cell Research Radio Broadcast Glenbrook South 2013 John, Alex – Video

New take on efficient delivery in regenerative medicine

Posted: Published on October 23rd, 2013

Oct. 22, 2013 An international research group has successfully tested the use of a new type of porous material for the efficient delivery of key molecules to transplanted cells derived from stem cells. These results can lead to improvements in the way stem cell-based neurodegenerative diseases are treated. A group of researchers based in Sweden, Denmark and Japan has successfully tested in animal models the use of a new type of porous material for the efficient delivery of key molecules to transplanted cells derived from stem cells. The researchers have developed a novel technological approach for the local delivery of exogenous trophic factor mimetics to transplanted cells using specifically designed silica nanoporous particles. This is potentially a versatile and widely applicable strategy for the efficient differentiation and functional integration of stem cell derivatives upon transplantation, and it can serve as a foundation for improving stem cell-based neuroregenerative protocols, for example Parkinson's disease. "We are working to provide standard and reproducible methods for the differentiation and implementation of Stem Cell therapies using this type of approach, which couples material science with regenerative medicine," said Dr. Alfonso Garcia-Bennett, one of the leading authors of the study currently working at the Department of … Continue reading →

Posted in Stem Cell Research | Comments Off on New take on efficient delivery in regenerative medicine

StemCells, Inc. to Present at Leading Conference on Neuroregeneration in Barcelona

Posted: Published on October 23rd, 2013

NEWARK, Calif., Oct. 22, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that Ann Tsukamoto, Ph.D., Executive Vice President, Scientific and Strategic Alliances at StemCells, will speak at the B-Debate International Center for Scientific Debate Barcelona,to be held October 23-24 in Barcelona, Spain. Dr. Tsukamoto will participate on October 23 in the forum "Neuroregeneration: Is There Already A Translational Experience in Clinical Practice?" and will make a presentation on the Company's clinical development programs. The goal of the B-Debate International Center for Scientific Debate Barcelona is to promote the exchange of information about neuroregeneration among cutting edge researchers in basic science, translational research, and clinical innovation. The B-Debate is organized by BIOCAT, the organization that coordinates and promotes the biotechnology, biomedicine, and medical technology sector in Catalonia, and La Caixa Foundation, in collaboration with the Institute Guttmann, a leading hospital for the treatment and rehabilitation of patients with spinal cord injury, brain damage, or other serious neurological disability. The Institute Guttmann is affiliated with the Autonomous University of Barcelona. About StemCells, Inc. StemCells, Inc. is engaged in the research, development, and commercialization of … Continue reading →

Posted in Stem Cell Research | Comments Off on StemCells, Inc. to Present at Leading Conference on Neuroregeneration in Barcelona

Life Stem Genetics is Pleased to Announce That It Has Completed the First $500,000 Private Placement of the Recently …

Posted: Published on October 23rd, 2013

LOS ANGELES--(BUSINESS WIRE)-- Life Stem Genetics (LIFS) is pleased to announce that it has completed and received the first $500,000 of the recently announced $1mm Private Placement. Our company is very happy to receive the first half of our recent private placement and hopes to close the additional $500,000 in the coming weeks. The money will be used to attract additional affiliate offices country wide and to invest in various areas of research and development in moving our company's plans forward. About Life Stem Genetics Life Stem Genetics (LSG) is a progressive health care company that focuses on healing with a patients own Stem Cells. Stem Cells for years have been known to heal a variety of ailments successfully and now it is being offered as an efficient and painless way to treat many different illnesses ranging from orthopedic injuries, neurological disorders such as Parkinsons and Alzheimers, Cancer, Plastic Surgery, Age Management, Arthritis, Diabetes, Cardiology, COPD, MS, Urology, and many more. Stem Cell Therapy and LSGs proprietary techniques have experienced some of the best results in the industry, helping to repair or re-program damaged or diseased tissues and organs. LSGs stem cell specialist has performed thousands of stem cell treatments, … Continue reading →

Comments Off on Life Stem Genetics is Pleased to Announce That It Has Completed the First $500,000 Private Placement of the Recently …

Stephan Jakober appointed to the Supervisory Board of MagForce AG

Posted: Published on October 23rd, 2013

Berlin, Germany, October 22, 2013 - MagForce AG (Frankfurt, Xetra: MF6), a leading medical device company in the area of nanotechnology with a focus on oncology, today announced details on the change in the Company`s Supervisory Board. Dr Jan zur Hausen stepped back from his membership position on September 13, 2013, due to personal reasons. The county court Berlin-Charlottenburg appointed Stephan Jakober as new Supervisory Board member. Stephan Jakober is Chief Financial Officer of Film House Germany AG, a Berlin-based production company for international and German movies, and works as consultant vor CIB Beratung AG (Zurich) in the area of Private Equity, Corporate Finance and Mergers & Acquisition. Prior to that, Stephan Jakober was reponsible for investments in medium-sized enterprises for different European Private Equity Funds as Investment Director. Stephan Jakober studied Business Administration at the University of St Gallen (HSG). About MagForce AG MagForce AG is a leading medical device company in the field of nanomedicine in oncology, listed in the entry standard (MF6). The Company`s proprietary, NanoTherm therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm, NanoPlan, and NanoActivator are components of the therapy and have received … Continue reading →

Comments Off on Stephan Jakober appointed to the Supervisory Board of MagForce AG

Page 4,827«..1020..4,8264,8274,8284,829..4,8404,850..»